text_1: Epigenetic modulating agents (EMAs) modulate antitumor immune response in a cancer model system.
text_2: The addition of an HDACi to AZA enhances the modulation of the immune microenvironment, specifically increasing T and NK cell activation and reducing macrophages over AZA treatment alone, while further increasing the survival of the mice.